Current clinical practice in antibiotic treatment of Staphylococcus aureus bacteraemia: results from a survey in five European countries

• Published in: Journal of antimicrobial chemotherapy 2022-09, Vol.77 (10), p.2827-2834
• Main Authors: Buis, D T P, Prins, J M, Betica-Radic, L, de Boer, M G J, Ekkelenkamp, M, Kofteridis, D, Peiffer-Smadja, N, Schouten, J, Spernovasilis, N, Tattevin, P, ten Oever, J, Sigaloff, K C E
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - therapeutic use; Bacteremia - complications; Bacteremia - drug therapy; Fluorodeoxyglucose F18 - therapeutic use; Humans; Life Sciences; Microbiology and Parasitology; Positron Emission Tomography Computed Tomography; Rifampin - therapeutic use; Staphylococcal Infections - complications; Staphylococcal Infections - drug therapy; Staphylococcus aureus; Surveys and Questionnaires
• ISSN: 0305-7453; 1460-2091
• DOI: 10.1093/jac/dkac237

Abstract Objectives To determine clinical practice variation and identify knowledge gaps in antibiotic treatment of Staphylococcus aureus bacteraemia (SAB). Methods A web-based survey with questions addressing antibiotic treatment of SAB was distributed through the ESGAP network among infectious disease specialists, clinical microbiologists and internists in Croatia, France, Greece, the Netherlands and the UK between July 2021 and November 2021. Results A total number of 1687 respondents opened the survey link, of whom 677 (40%) answered at least one question. For MSSA and MRSA bacteraemia, 98% and 94% preferred initial monotherapy, respectively. In patients with SAB and non-removable infected prosthetic material, between 80% and 90% would use rifampicin as part of the treatment. For bone and joint infections, 65%–77% of respondents would consider oral step-down therapy, but for endovascular infections only 12%–32% would. Respondents recommended widely varying treatment durations for SAB with different foci of infection. Overall, 48% stated they used 18F-fluorodeoxyglucose positron emission tomography/CT (18F-FDG-PET/CT) to guide antibiotic treatment duration. Persistent bacteraemia was the only risk factor for complicated SAB that would prompt a majority to extend treatment from 2 to 4–6 weeks. Conclusions This survey in five European countries shows considerable clinical practice variation between and within countries in the antibiotic management of SAB, in particular regarding oral step-down therapy, choice of oral antibiotic agents, treatment duration and use of 18F-FDG-PET/CT. Physicians use varying criteria for treatment decisions, as evidence from clinical trials is often lacking. These areas of practice variation could be used to prioritize future studies for further improvement of SAB care.